Chad Winters
Known title: VP, CAO & Corporate ControllerCIK: 0001811424
Associated companies
Transaction History
| WST | ▲ Buy | Option Exercise | 896 | $155K | 4/27/2026 | View on chart |
| WST | ▼ Sell | Open Market | 896 | $269K | 4/27/2026 | View on chart |
| WST | ▲ Buy | Option Exercise | 89 | — | 2/20/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 30 | $7K | 2/20/2026 | View on chart |
| WST | ▲ Buy | Grant | 150 | $0 | 2/17/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 51 | $12K | 2/17/2026 | View on chart |
| WST | ▼ Sell | Tax Withholding | 28 | $6K | 2/18/2025 | View on chart |
| WST | ▲ Buy | Option Exercise | 82 | $17K | 2/18/2025 | View on chart |
| WST | ▲ Buy | Option Exercise | 675 | $117K | 3/11/2024 | View on chart |
| WST | ▼ Sell | Open Market | 815 | $292K | 3/11/2024 | View on chart |
| WST | ▲ Buy | Grant | 179 | $0 | 2/20/2024 | View on chart |
| WST | ▼ Sell | Open Market | 1,013 | $354K | 12/1/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 341 | $59K | 12/1/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 456 | $65K | 12/1/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 872 | $296K | 5/30/2023 | View on chart |
| WST | ▲ Buy | Option Exercise | 872 | $125K | 5/30/2023 | View on chart |
| WST | ▼ Sell | Tax Withholding | 10 | $4K | 5/5/2023 | View on chart |
| WST | ▲ Buy | Grant | 476 | $146K | 2/21/2023 | View on chart |
| WST | ▼ Sell | Tax Withholding | 47 | $11K | 10/31/2022 | View on chart |
| WST | ▼ Sell | Tax Withholding | 10 | $3K | 5/5/2022 | View on chart |
| WST | ▲ Buy | Grant | 414 | $153K | 2/22/2022 | View on chart |
| WST | ▼ Sell | Tax Withholding | 47 | $20K | 10/29/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
West Pharmaceutical Services noted in analyst upgrade and market rally
West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.
West Pharmaceutical Services noted in analyst upgrade and market rally. West Pharmaceutical Services has risen about 36% year-to-date, drawing attention in recent market round-ups. TD Cowen kept its positive stance and lifted its price target to $420, citing the company's performance. The stock also appeared in CNBC’s final‑trade segment and in a dividend‑growth stock list, highlighting investor interest.